A case series on tofacitinib-induced weight gain

Kanisha Shah, Dhaiwat Shukla, Manish Patel, Supriya MalhotraIndian Journal of Pharmacology 2023 55(4):263-265 Janus kinase inhibitor tofacitinib belongs to a group of targeted synthetic disease-modifying anti-rheumatic drugs, also known as small molecule inhibitors. They are oral drugs with a novel strategy to treat inflammatory diseases. The major concern with the use of these drugs is a high risk for infections and other potential side effects. Here, we have focused on reporting one of the rare side effects of tofacitinib, weight gain. We have reported six cases of tofacitinib-induced weight gain in patients of ankylosing spondylitis, rheumatoid arthritis, and vasculitis.
Source: Indian Journal of Pharmacology - Category: Drugs & Pharmacology Authors: Source Type: research